Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints

Urology

Volumn 57, Issue 4 SUPPL. 1, 2001, Pages 216-219

  Keegan, Patricia ^a,c   Loughman, Barbara E ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLURBIPROFEN;

ARTICLE; CLINICAL TRIAL; DRUG INTERACTION; DRUG SCREENING; HUMAN; MALE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FLURBIPROFEN; HUMANS; MALE; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 0035321471     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(00)00978-x     Document Type: Article

References (5)

1. Wechter WJ, Kantoci D, Murray ED Jr, et al: R-flurbiprofen chemoprevention and treatment in intestinal adenomas in the APCmin/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 57: 4316-4324, 1997.
2. Wechter WJ, Leipold DD, Murray ED Jr, et al: E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60: 2203-2208, 2000.
3. Lotsch J, Geisslinger G, Mohammadian P, et al: Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects. Br J Clin Pharmacol 40: 339-346, 1995.
4. Jerussi T, Caubet J, McCray J, et al: Clinical endoscopic evaluation of gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen, and paracetomol. J Clin Pharmocokinet 28: 19S-24S, 1998.
5. Bubley GJ, Carucci M, Dahut W, et al: Eligibility and response guidelines for phase 11 clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467, 1999.